Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
Luo LX, Fan XX, Li Y, Peng X, Ji YC, Hsiao WW, Liu L, Leung EL, Yao XJ.
Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by <i>in silico</i> screening in non-small cell lung cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its downstream signaling pathway and thus induce cell apoptosis.